|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 281, Issue 46, 35030-35038, November 17, 2006
Identification of an AHNAK Binding Motif Specific for the Annexin2/S100A10 Tetramer*![]() ¶![]() ¶![]() ¶![]() ¶![]() ¶1![]() ¶2
From the
The Annexin2 tetramer (A2t), which consists of two Annexin2 molecules bound to a S100A10 dimer, is implicated in membrane-trafficking events. Here, we showed using a yeast triple-hybrid experiment and in vitro binding assay that Annexin2 is required for strong binding of S100A10 to the C-terminal domain of the protein Ahnak. We also revealed that this effect involves only the Annexin2 N-terminal tail, which is implicated in S100A10/Annexin2 tetramerization. The minimal A2t binding motif (A2tBP1) in Ahnak was mapped to a 20-amino acid peptide, and this peptide is highly specific for A2t. We also identified a second A2t binding motif (A2tBP2) present in the N-terminal domain of Ahnak, which binds to A2t, albeit with less affinity. When overexpressed as an EGFP fusion protein in MDCK cells, A2tBPs cofractionate in a calcium-dependent manner and co-immunoprecipitate with S100A10 and Annexin2. In living cells, A2tBPs target EGFP to the cytoplasm as does Annexin2. In response to oxidative and mechanical stress, EGFP-A2tBPs relocalize within minutes to the plasma membrane; a behavior shared with Annexin2-GFP. These results suggest that the A2t complex exists within the cytoplasm of resting living cells and that its localization at the plasma membrane relies on cellular signaling. Together, our data demonstrate that A2tBP1 is a specific A2t complex binding domain and may be a powerful tool to help elucidate A2t structure and cellular functions.
Received for publication, July 10, 2006 , and in revised form, September 7, 2006. * This study has been supported by Grant 5643 from the Association pour la Recherche sur le Cancer (ARC) (to C. D.) and Grant 11597 from the Association Française contre les Myopathies (AFM). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence may be addressed: INSERM EMI 0104/TS-DRDC, CEA Grenoble, 17 rue des Martyrs, 38054 Grenoble Cedex 9, France. Tel.: 33-4-38-78-47-27; Fax: 33-4-38-78-50-58; E-mail: jbaudier{at}cea.fr. 2 To whom correspondence may be addressed: INSERM EMI 0104/TS-DRDC, CEA Grenoble, 17 rue des Martyrs, 38054 Grenoble Cedex 9, France. Tel.: 33-4-38-78-47-27; Fax: 33-4-38-78-50-58; E-mail: cdelphin{at}cea.fr.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||